COMP <GO>
INDV vs MRK // NET PROFIT MARGIN
Indivior Pharmaceuticals Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: INDV 5
— MRK 9
▲ NET PROFIT MARGIN LEADER: MRK
LAST: $35.37 (+0.34%) • MKT CAP: $4.16B
net-margins
16.90%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
net-margins
28.10%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INDV VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INDV | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 80.20% | 74.80% | +5.40 | INDV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 62.20% | 20.70% | +41.50 | INDV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 13.4x | 15.3x | -1.90 | INDV | /valuation <GO> |
| Free Cash Flow Yield | -2.24% | 3.42% | -5.66 | MRK | /fcf-yield <GO> |
| Operating Margin | 21.10% | 34.30% | -13.20 | MRK | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 16.90% | 28.10% | -11.20 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 4.30% | 1.30% | +3.00 | INDV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.13 | 5.19 | -2.06 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 6.60% | +0.80 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.2 | 56.9 | -4.62 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 0.92 | +0.23 | INDV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.4x | 18.4x | 0.00 | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.16B | $361.02B | -$356.86B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INDV REV | MRK REV | INDV GROSS % | MRK GROSS % | INDV FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.24B | $65.01B | 80.2% | 74.8% | -$93.0M | $12.36B |
| FY 2024 | $1.19B | $64.17B | 80.6% | 76.3% | $7.0M | $18.10B |
| FY 2023 | $1.09B | $60.12B | 44.0% | 44.0% | -$349.2M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INDV // BETA 1.15
MRK // BETA 0.92